Open an account Help & support Register Account summary Log out
Skip Header
Home Stock market news

Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Director dealings: Astrazeneca CEO raises stake

Fri 18 Sep 2026 14:14

(Sharecast News) - Astrazeneca revealed on Friday that chief executive Pascal Soriot had acquired 60,000 ordinary shares in the FTSE 100-listed drugmaker. Soriot, who took over as CEO in October 2012, purchased the shares at an average price of 12,102p each, for a total value of £7.26m.

As of 1540 BST, Astrazeneca shares were up 0.82% at 12,530p.

Reporting by Iain Gilbert at Sharecast.com

Top Director Buys

Astrazeneca (AZN) Director name: Soriot,Pascal Amount purchased: 60,000 @ 12,102.00p Value: £7,261,199.80

Trustpilot Group (TRST) Director name: Roy ,Marcus Amount purchased: 45,436 @ 218.98p Value: £99,493.93

Trustpilot Group (TRST) Director name: Byng-Thorne,Zillah Amount purchased: 27,746 @ 215.14p Value: £59,692.75

Trustpilot Group (TRST) Director name: Byng-Thorne,Zillah Amount purchased: 17,854 @ 222.87p Value: £39,791.21

Tmt Investments (TMT) Director name: Selegenev,Alexander Amount purchased: 10,000 @ $3.23 Value: $32,300.00

Tmt Investments (TMT) Director name: Selegenev,Alexander Amount purchased: 3,000 @ $3.46 Value: $10,380.00

Domino's Pizza Group (DOM) Director name: Perriss,Robyn Amount purchased: 4,850 @ 204.50p Value: £9,918.40

Top Director Sells

Share this article

Related Sharecast Articles

Fri 25 Sep 2026 12:38
Director dealings: Trufin CEO snaps up more shares
(Sharecast News) - Trufin revealed on Friday that chief executive James van den Bergh had acquired 25,000 ordinary shares in the AIM-listed software firm.
Thu 24 Sep 2026 09:19
Director dealings: Oxford Biomedica chair ups stake
(Sharecast News) - The largest market purchase of shares in London on Thursday came from Oxford Biomedica's chair Roch Doliveux. who upped his stake in the cell and gene therapy company after a sharp drop in the stock over the year to date.
Wed 23 Sep 2026 14:23
Director dealings: Intercede's Dan O'Brien raises stake
(Sharecast News) - Intercede Group revealed on Wednesday that non-executive director Dan O'Brien had acquired 22,070 ordinary shares in the AIM-listed cybersecurity software firm.
Tue 22 Sep 2026 13:29
Director dealings: Foreterra non-executive director snaps up shares
(Sharecast News) - Forterra revealed on Tuesday that non-executive director Gavin Hill had acquired 28,944 ordinary shares in the London-listed building products manufacturer.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Awards

Award 1
Award 2
Award 3

Policies and important information

Accessibility | Conflicts of interest statement | Consumer Duty Target Market | Consumer Duty Value Assessment Statements | Cookie policy | Diversity, Equity & Inclusion | Diversity, Equity & Inclusion Reports | Doing Business with Fidelity | Investing in Fidelity funds | Legal information | Modern slavery | Mutual respect policy | Privacy statement | Remuneration policy | Statutory and Regulatory disclosures | Whistleblowing programme

Please remember that past performance is not necessarily a guide to future performance, the performance of investments is not guaranteed, and the value of your investments can go down as well as up, so you may get back less than you invest. When investments have particular tax features, these will depend on your personal circumstances and tax rules may change in the future. This website does not contain any personal recommendations for a particular course of action, service or product. You should regularly review your investment objectives and choices and, if you are unsure whether an investment is suitable for you, you should contact an authorised financial adviser. Before opening an account, please read the ‘Doing Business with Fidelity’ document which incorporates our client terms. Prior to investing into a fund, please read the relevant key information document or Product Summary document which contains important information about the fund.

This website is issued by Financial Administration Services Limited, which is authorised and regulated by the Financial Conduct Authority (FCA) (FCA Register number 122169) and registered in England and Wales under company number 1629709 whose registered address is Beech Gate, Millfield Lane, Lower Kingswood, Tadworth, Surrey, KT20 6RP.

© FIL Limited 2026